← back to search

Carlo Pozzilli

Cardiff University · GB
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research focused on Multiple sclerosis and Pregnancy, with related work in Natalizumab, Tolerability, Expanded Disability Status Scale. Notable publications include 'Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder', 'Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion', and 'Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial'.
h-index
citations
1,629
works
31
NIH funding
primary concept
email

Recent publications

The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors
Frontiers in Immunology 2025cited by 15position: middledoi
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus
Journal of Neurology 2025cited by 6position: middledoi
Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists
European Journal of Neurology 2025cited by 4position: middledoi
Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study
Neurotherapeutics 2025cited by 4position: middledoi
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty
Neurology and Therapy 2025cited by 3position: middledoi
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study
Therapeutic Advances in Neurological Disorders 2025cited by 0position: middledoi
Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis
Diagnostics 2024cited by 12position: lastdoi
Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder
Annals of Neurology 2023cited by 184position: middledoi
Multiple Sclerosis Progression and Relapse Activity in Children
JAMA Neurology 2023cited by 39position: middledoi
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study
Journal of Neurology Neurosurgery & Psychiatry 2023cited by 17position: middledoi
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
Journal of Neurology 2022cited by 179position: middledoi
Diagnosis and treatment of progressive multiple sclerosis: A position paper
European Journal of Neurology 2022cited by 49position: firstdoi
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide
Frontiers in Immunology 2022cited by 31position: middledoi
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
Neurological Sciences 2022cited by 30position: middledoi
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
Journal of Neurology Neurosurgery & Psychiatry 2022cited by 29position: middledoi
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
Frontiers in Immunology 2022cited by 11position: middledoi
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Neurology 2020cited by 104position: middledoi
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
Journal of Neurology 2018cited by 54position: middledoi
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
Journal of Neurology 2017cited by 58position: middledoi
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study
PLoS ONE 2016cited by 6position: middledoi
Natalizumab in the pediatric MS population: results of the Italian registry
BMC Neurology 2015cited by 90position: middledoi
An overview of pregnancy‐related issues in patients with multiple sclerosis
European Journal of Neurology 2015cited by 61position: firstdoi
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
Journal of Neurology Neurosurgery & Psychiatry 2014cited by 151position: middledoi
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs
Journal of Neurology Neurosurgery & Psychiatry 2014cited by 84position: middledoi
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study
BMC Neurology 2014cited by 36position: middledoi
Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group
Neurological Sciences 2014cited by 2position: middledoi
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases
Multiple Sclerosis Journal 2013cited by 66position: middledoi
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group
Neurological Sciences 2013cited by 37position: middledoi
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
BMC Neurology 2012cited by 98position: middledoi
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
BMC Neurology 2012cited by 91position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

María Trojano · University of Bari Aldo Moro7 papers (2012–2025)Francesco Patti · Université Claude Bernard Lyon 17 papers (2012–2025)Celia Oreja‐Guevara · Monash University6 papers (2022–2025)Maura Pugliatti · Hospital for Sick Children6 papers (2015–2025)Maria Pia Amato · University of Alabama at Birmingham6 papers (2012–2022)Massimo Filippi · McGill University Health Centre5 papers (2013–2025)Angelo Ghezzi · Università degli Studi del Piemonte Orientale “Amedeo Avogadro”5 papers (2012–2015)Lucia Moiola · University of Leicester5 papers (2012–2015)Patrick Vermersch · UNSW Sydney5 papers (2022–2025)Alessandra Lugaresi · University of Ferrara5 papers (2012–2016)Laura Airas · Turku University Hospital5 papers (2022–2025)Bart Van Wijmeersch · Georgetown University4 papers (2022–2025) · 4 papers (2012–2016)Paolo Gallo · University of Padua4 papers (2015–2025) · 4 papers (2022–2025) · 3 papers (2012–2014)Claudio Solaro · Gene Therapy Laboratory3 papers (2012–2014)Maria Rosaria Tola · Istituti di Ricovero e Cura a Carattere Scientifico3 papers (2012–2014)Diego Centonze · Agostino Gemelli University Polyclinic3 papers (2017–2025)Melinda Magyari · Aarhus University3 papers (2022–2025)